Open-label adalimumab + MTX slowed radiographic progression through week @ in both groups , but patients who received adalimumab + MTX throughout the study exhibited less radiographic progression than those who received placebo + MTX during the first @ weeks ( mean mTSS at week @ = @ vs @ , P < @ ) .